期刊
CARDIOVASCULAR RESEARCH
卷 98, 期 3, 页码 334-343出版社
OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvt036
关键词
Arginase; Nitric oxide; Reactive oxygen species; Atherosclerosis; Ischaemia; Diabetes mellitus; Hypertension
资金
- Swedish Research Council Medicine
- Swedish Heart and Lung Foundation
- European Foundation for the Study of Diabetes
- Stockholm County Council (ALF)
- Karolinska Institutet/Stockholm County Council Cardiovascular Programme
- Novo Nordisk Foundation
- Gustav V and Queen Victoria Foundation
Functional integrity of the vascular endothelium is of fundamental importance for normal vascular function. A key factor regulating endothelial function is the bioavailability of nitric oxide (NO). Recently, the enzyme arginase has emerged as an important regulator of NO production by competing for l-arginine, which is a substrate for both arginase and NO synthase. Increased activity of arginase may reduce the availability of l-arginine for NO synthase, thus reducing NO production, increasing formation of reactive oxygen species, and leading ultimately to endothelial dysfunction. Increased activity and expression of arginase have been demonstrated in several pathological cardiovascular conditions, including hypertension, pulmonary arterial hypertension, atherosclerosis, myocardial ischaemia, congestive heart failure, and vascular dysfunction in diabetes mellitus. Experimental studies have demonstrated that inhibition of arginase under these conditions increases NO bioavailability, reduces oxidative stress, improves vascular function, and protects against ischaemiareperfusion injury. Initial clinical interventional studies are also promising. The purpose of this review is to discuss the role of arginase in cardiovascular pathologies, its contribution to the development of several cardiovascular disease states and the feasibility of using arginase inhibition as a therapeutic strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据